Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latanoprost vs Timolol in Glaucoma/Ocular Hypertension
NCT00751127Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 1993
- Primary completion
- Feb 1994
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of latanoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Pfizer. Primary endpoint: Intraocular Pressure at 6 months. Started Jan 1993; status: completed.
02
Drugs
latanoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT00751127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00751127.